Withdrawn psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Withdrawn is a registry status. The study was stopped before the first participant was enrolled. Status is reported by the study team and can change.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 47 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 14 |
| MDMA | 6 |
| DMT | 1 |
| 5-MeO-DMT | 1 |
| Ketamine | 26 |
| Ibogaine | 1 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 5 | 11% |
| Phase 1 | 8 | 17% |
| Phase 2 | 21 | 45% |
| Phase 3 | 5 | 11% |
| Phase 4 | 3 | 6% |
| Not applicable | 3 | 6% |
| Not reported | 2 | 4% |
Countries
Country is taken from the study's linked research site. 3 of 47 records have no country on file. The top 6 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 38 | 81% |
| Canada | 2 | 4% |
| Austria | 1 | 2% |
| Brazil | 1 | 2% |
| France | 1 | 2% |
| Jamaica | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 12 |
| 2020 to 2023 | 22 |
| 2015 to 2019 | 8 |
| 2010 to 2014 | 4 |
| Before 2010 | 1 |
Study design
- 45 interventional and 2 observational studies.
- Median planned or actual enrolment is 55 participants (range 20 to 90, across 4 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 16 |
| Trauma and PTSD | 7 |
| Suicidal thoughts | 5 |
| Other substance use | 4 |
| Anxiety | 2 |
| Cancer and end of life | 2 |
| Healthy volunteers | 2 |
| Alcohol use | 1 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT06005662 | Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | Withdrawn | Phase 2 | United States | 2027-04 |
| NCT07484906 | Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | Withdrawn | Phase 2 | United States | 2026-05 |
| NCT04454684 | A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders | Withdrawn | Phase 2 | United States | 2026-02 |
| NCT06048263 | The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series | Withdrawn | Phase 2 | United States | 2025-10 |
| NCT05991232 | Repeated Neurocognitive Measurements in Depressed Patients | Withdrawn | Phase 1 | Not reported | 2025-10 |
| NCT06810765 | Trifecta Research Study | Withdrawn | Phase 2 | United States | 2025-09 |
| NCT06353282 | MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | Withdrawn | Phase 2 | United States | 2025-07 |
| NCT05562973 | Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder | Withdrawn | Phase 1 | United States | 2025-01 |
| NCT04073433 | Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2) | Withdrawn | Phase 1 | United States | 2024-12 |
| NCT06560658 | Optimizing Microdosing and Meditation | Withdrawn | Not applicable | United States | 2024-10 |
| NCT03752918 | The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. | Withdrawn | Phase 1 | United States | 2024-05 |
| NCT05675800 | Psilocybin for Major Depressive Disorder | Withdrawn | Phase 2 | United States | 2024-01 |
| NCT06036511 | Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD | Withdrawn | Phase 1 | United States | 2023-12 |
| NCT05242029 | Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use | Withdrawn | Phase 2 | United States | 2023-12 |
| NCT05344625 | Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress | Withdrawn | Early Phase 1 | United States | 2023-10 |
| NCT05554627 | VA Aripiprazole vs Esketamine for Treatment Resistant Depression | Withdrawn | Phase 4 | United States | 2023-10 |
| NCT05173831 | Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans | Withdrawn | Phase 2 | United States | 2023-09 |
| NCT05661669 | Ketamine for the Treatment for Alcohol Use Disorder in the ED | Withdrawn | Phase 2 | United States | 2023-09 |
| NCT05949554 | Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine. | Withdrawn | Not reported | France | 2023-09 |
| NCT05227742 | Exploratory Study of Low Dose Psilocybin | Withdrawn | Early Phase 1 | United States | 2023-08 |
| NCT05601648 | PET Synaptogenesis After Psilocybin In DEpression Recovery | Withdrawn | Phase 2 | United States | 2023-07 |
| NCT05467761 | Bioavailability Study of Psilocybin in Normal Adults | Withdrawn | Phase 1 | United States | 2023-06 |
| NCT05438758 | Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study | Withdrawn | Phase 2 | Canada | 2023-01 |
| NCT05252598 | Mood and Cognitive Effects of Psilocybin in Healthy Participants | Withdrawn | Early Phase 1 | Not reported | 2023-01 |
| NCT05594667 | Effect of SSRIs on Response to Psilocybin Therapy | Withdrawn | Phase 2 | Canada | 2023-01 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable